Full metadata record
DC poleHodnotaJazyk
dc.contributor.authorLorentzon, Mattias
dc.contributor.authorBranco, Jaime
dc.contributor.authorBrandi, Maria Luisa
dc.contributor.authorBruyère, Olivier
dc.contributor.authorChapurlat, Roland
dc.contributor.authorCooper, Cyrus
dc.contributor.authorCortet, Bernard
dc.contributor.authorDiez-Perez, Adolfo
dc.contributor.authorFerrari, Serge
dc.contributor.authorGasparik, Andrea
dc.contributor.authorHerrmann, Markus
dc.contributor.authorJorgensen, Niklas Rye
dc.contributor.authorKanis, John
dc.contributor.authorKaufman, Jean-Marc
dc.contributor.authorLaslop, Andrea
dc.contributor.authorLocquet, Médéa
dc.contributor.authorMatijevic, Radmila
dc.contributor.authorMcCloskey, Eugene
dc.contributor.authorMinisola, Salvatore
dc.contributor.authorPikner, Richard
dc.contributor.authorReginster, Jean-Yves
dc.contributor.authorRizzoli, René
dc.contributor.authorSzulc, Pawel
dc.contributor.authorVlaskovska, Mila
dc.contributor.authorCavalier, Etienne
dc.date.accessioned2022-03-07T11:00:20Z-
dc.date.available2022-03-07T11:00:20Z-
dc.date.issued2019
dc.identifier.citationLORENTZON, M. BRANCO, J. BRANDI, ML. BRUYÈRE, O. CHAPURLAT, R. COOPER, C. CORTET, B. DIEZ-PEREZ, A. FERRARI, S. GASPARIK, A. HERRMANN, M. JORGENSEN, NR. KANIS, J. KAUFMAN, J. LASLOP, A. LOCQUET, M. MATIJEVIC, R. MCCLOSKEY, E. MINISOLA, S. PIKNER, R. REGINSTER, J. RIZZOLI, R. SZULC, P. VLASKOVSKA, M. CAVALIER, E. Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. Advances in Therapy, 2019, roč. 36, č. 10, s. 2811-2824. ISSN: 0741-238Xcs
dc.identifier.issn0741-238X
dc.identifier.uri2-s2.0-85071416284
dc.identifier.urihttp://hdl.handle.net/11025/47063
dc.format14 s.cs
dc.format.mimetypeapplication/pdf
dc.language.isoenen
dc.publisherSpringeren
dc.relation.ispartofseriesAdvances in Therapyen
dc.rights© authorsen
dc.titleAlgorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosisen
dc.typečlánekcs
dc.typearticleen
dc.rights.accessopenAccessen
dc.type.versionpublishedVersionen
dc.description.abstract-translatedINTRODUCTION: Increased biochemical bone turnover markers (BTMs) measured in serum are associated with bone loss, increased fracture risk and poor treatment adherence, but their role in clinical practice is presently unclear. The aim of this consensus group report is to provide guidance to clinicians on how to use BTMs in patient evaluation in postmenopausal osteoporosis, in fracture risk prediction and in the monitoring of treatment efficacy and adherence to osteoporosis medication. METHODS: A working group with clinical scientists and osteoporosis specialists was invited by the Scientific Advisory Board of European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). RESULTS: Serum bone formation marker PINP and resorption marker βCTX-I are the preferred markers for evaluating bone turnover in the clinical setting due to their specificity to bone, performance in clinical studies, wide use and relatively low analytical variability. BTMs cannot be used to diagnose osteoporosis because of low sensitivity and specificity, but can be of value in patient evaluation where high values may indicate the need to investigate some causes of secondary osteoporosis. Assessing serum levels of βCTX-I and PINP can improve fracture prediction slightly, with a gradient of risk of about 1.2 per SD increase in the bone marker in addition to clinical risk factors and bone mineral density. For an individual patient, BTMs are not useful in projecting bone loss or treatment efficacy, but it is recommended that serum PINP and βCTX-I be used to monitor adherence to oral bisphosphonate treatment. Suppression of the BTMs greater than the least significant change or to levels in the lower half of the reference interval in young and healthy premenopausal women is closely related to treatment adherence. CONCLUSION: In conclusion, the currently available evidence indicates that the principal clinical utility of BTMs is for monitoring oral bisphosphonate therapy.en
dc.subject.translatedRheumatologyen
dc.subject.translatedP1NPen
dc.subject.translatedOsteoporosisen
dc.subject.translatedCTXen
dc.subject.translatedBone biomarkeren
dc.subject.translatedBoneen
dc.subject.translatedAlgorithmen
dc.identifier.doi10.1007/s12325-019-01063-9
dc.type.statusPeer-revieweden
dc.identifier.document-number488950000018
dc.identifier.obd43926710
Vyskytuje se v kolekcích:Články / Articles (KAZ)
OBD

Soubory připojené k záznamu:
Soubor VelikostFormát 
Lorentzon2019_Article_AlgorithmForTheUseOfBiochemica.pdf433,62 kBAdobe PDFZobrazit/otevřít
Zobrazit minimální záznam Zobrazit statistiky


Použijte tento identifikátor k citaci nebo jako odkaz na tento záznam: http://hdl.handle.net/11025/47063

Všechny záznamy v DSpace jsou chráněny autorskými právy, všechna práva vyhrazena.

hledání
navigace
  1. DSpace at University of West Bohemia
  2. Publikační činnost / Publications
  3. OBD